{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:09:27Z","timestamp":1792696167005,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.radonc.2025.111238","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:08Z","timestamp":1761870308000},"page":"111238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Carbon ion therapy for pancreatic cancer with risk-adapted dose escalation: initial clinical experience"],"prefix":"10.1016","volume":"214","author":[{"given":"I-Chun","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Mei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Hung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7983-415X","authenticated-orcid":false,"given":"Yu-Wen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-I","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mung-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ming","family":"Shyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Pin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-E","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Huang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Jung","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ping","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko-Han","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Jung","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Yuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Fan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng-Li","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111238_b0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2025.111238_b0010","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.111238_b0015","unstructured":"Cancer Stat Facts: Pancreatic Cancer. 2024."},{"key":"10.1016\/j.radonc.2025.111238_b0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated Projection of US Cancer Incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.radonc.2025.111238_b0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","article-title":"Optimizing the outcomes of pancreatic cancer surgery","volume":"16","author":"Strobel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174326","article-title":"Efficacy and safety of neoadjuvant gemcitabine plus nab-paclitaxel in borderline resectable and locally advanced pancreatic cancer-a systematic review and meta-analysis","volume":"13","author":"Damm","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111238_b0035","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.111238_b0040","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0045","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","article-title":"A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)","volume":"181","author":"Ozaka","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2025.111238_b0050","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","article-title":"Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial","volume":"6","author":"Kunzmann","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.radonc.2025.111238_b0055","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: ECOG 4201","volume":"29","author":"Loehrer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0060","first-page":"3001","article-title":"Evaluating the impact of chemoradiotherapy in LAPC: ECOG 4201","volume":"120","author":"Abrams","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.111238_b0065","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2025.111238_b0070","first-page":"1184","article-title":"Induction chemotherapy and radiation therapy in LAPC: LAP07 analysis","volume":"30","author":"Mukherjee","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0075","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13014-019-1309-x","article-title":"Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results","volume":"14","author":"Reyngold","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0085","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.111238_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.10.013","article-title":"Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial)","volume":"17","author":"Suker","year":"2019","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.radonc.2025.111238_b0095","article-title":"Stereotactic body radiotherapy for pancreatic cancer - a systematic review of prospective data","volume":"45","author":"Shouman","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0100","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17020191","article-title":"Dose-escalated SBRT for borderline and locally advanced pancreatic cancer: resectability rate and pathological results of a multicenter prospective study","volume":"17","author":"Salas-Salas","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111238_b0105","article-title":"Dosimetric predictors of acute and late gastrointestinal toxicities in stereotactic online adaptive magnetic resonance-guided radiotherapy (SMART) for locally advanced pancreatic adenocarcinoma","volume":"200","author":"D'Souza","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.600940","article-title":"Dosimetric feasibility study of dose escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) patients: it is time to raise the Bar","volume":"10","author":"Mazzarotto","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0115","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0360-3016(00)00803-8","article-title":"Pancreatic tumors show high levels of hypoxia","volume":"48","author":"Koong","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111238_b0120","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.radonc.2025.111238_b0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.radonc.2025.111238_b0130","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","article-title":"The pancreas cancer microenvironment","volume":"18","author":"Feig","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.111238_b0135","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1586\/17474124.2016.1117386","article-title":"The role of hypoxia in pancreatic cancer: a potential therapeutic target?","volume":"10","author":"Erkan","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.radonc.2025.111238_b0140","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0360-3016(98)00544-6","article-title":"Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy","volume":"44","author":"Kanai","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111238_b0145","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.radonc.2016.04.026","article-title":"Comparison of carbon-ion passive and scanning irradiation for pancreatic cancer","volume":"119","author":"Shiomi","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrclinonc.2009.183","article-title":"Charged particles in radiation oncology","volume":"7","author":"Durante","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0155","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/S1470-2045(14)70412-7","article-title":"Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience","volume":"16","author":"Kamada","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0160","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/jjco\/hys104","article-title":"A review of update clinical results of carbon ion radiotherapy","volume":"42","author":"Tsujii","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0165","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.radonc.2018.08.026","article-title":"A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer","volume":"129","author":"Shinoto","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0170","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.ijrobp.2018.04.057","article-title":"Multi-institutional study of carbon-ion radiotherapy for locally advanced pancreatic cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) study 1403 pancreas","volume":"101","author":"Kawashiro","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111238_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.708884","article-title":"Effectiveness of carbon ion radiation in locally advanced pancreatic cancer","volume":"11","author":"Liermann","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102857","article-title":"Carbon-ion radiotherapy combined with concurrent chemotherapy for locally advanced pancreatic cancer: a retrospective case series analysis","volume":"15","author":"Okamoto","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111238_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082213","article-title":"Survival outcomes and failure patterns in patients with inoperable non-metastatic pancreatic cancer treated with definitive radiotherapy","volume":"15","author":"Cao","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111238_b0190","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2025.0460","article-title":"Nonoperative management of technically resectable pancreatic cancer with ablative radiation therapy","author":"Reyngold","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0195","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1200\/JCO.2017.72.4948","article-title":"Potentially Curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"35","author":"Khorana","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0200","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.19.00946","article-title":"Potentially curable pancreatic adenocarcinoma: ASCO Clinical Practice Guideline Update","volume":"37","author":"Khorana","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0205","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/SLA.0000000000002600","article-title":"Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX","volume":"269","author":"Michelakos","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.radonc.2025.111238_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100552","article-title":"Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)","volume":"7","author":"Hartlapp","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.radonc.2025.111238_b0215","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00280-020-04165-2","article-title":"The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis","volume":"86","author":"Ye","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.radonc.2025.111238_b0220","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.hpb.2018.01.001","article-title":"Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy","volume":"20","author":"van Veldhuisen","year":"2018","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.radonc.2025.111238_b0225","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/SLA.0000000000003049","article-title":"Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer","volume":"271","author":"Tsai","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.radonc.2025.111238_b0230","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/SLA.0000000000005184","article-title":"Prognosis associated with CA19-9 response dynamics and normalization during neoadjuvant therapy in resected pancreatic adenocarcinoma","volume":"277","author":"Newhook","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.radonc.2025.111238_b0235","doi-asserted-by":"crossref","first-page":"166","DOI":"10.21037\/jgo.2019.03.02","article-title":"Proton beam radiotherapy for pancreas cancer","volume":"11","author":"Rutenberg","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.radonc.2025.111238_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102719","article-title":"Pancreatic cancer biomarkers: a pathway to advance in personalized treatment selection","volume":"125","author":"Brozos-V\u00e1zquez","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2025.111238_b0245","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/tgh.2020.04.03","article-title":"Pancreatic cancer and immune checkpoint inhibitors-still a long way to go","volume":"6","author":"Bian","year":"2021","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.radonc.2025.111238_b0250","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.radonc.2025.111238_b0255","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1097\/JS9.0000000000000877","article-title":"Pancreatic cancer: new approaches to drug therapy","volume":"110","author":"Picozzi","year":"2024","journal-title":"Int J Surg"},{"key":"10.1016\/j.radonc.2025.111238_b0260","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2057892","article-title":"Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice","volume":"11","author":"Zhou","year":"2022","journal-title":"Oncoimmunology"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025052429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025052429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:29:46Z","timestamp":1786537786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025052429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"alternative-id":["S0167814025052429"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111238","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carbon ion therapy for pancreatic cancer with risk-adapted dose escalation: initial clinical experience","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111238"}}